Skip to content

Gross margin at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
98.4%-0.2pp
ANI Pharmaceuticals logo
ANI PharmaceuticalsANIP
60.8%+1.5pp
BridgeBio Pharma logo
BridgeBio PharmaBBIO
95.1%-0.2pp
Agios Pharmaceuticals logo
Agios PharmaceuticalsAGIO
90%+2.5pp
Acadia Pharmaceuticals logo
Acadia PharmaceuticalsACAD
91.5%-0.6pp
HRO
HarrowHROW
74.1%-0.4pp

Other financials

Income statement

See full
Revenue$156.4M+7.5%
Gross profit$151.0M+7.1%
Operating income-$701.6M-3,405%
Net income-$721.8M-2,255,763%
EPS (diluted)-$2.98

Balance sheet

See full
Cash & equivalents$173.4M+62.2%
Total debt$411.8M+24.7%
Total equity-$553.8M-22.6%
Total assets$465.1M-3.1%

Cash flow

See full
Operating cash flow-$61.8M-125%
CapEx$403.0K+182%
Free cash flow-$62.2M-125%

Valuation

See full
Market cap$2.37B+52.3%
Enterprise value$2.6B+46.7%
P/S2.7×-0.4×

Profitability

See full
Operating margin-43.1%-49.7pp
Net margin-51.7%-69.7pp
FCF margin35%

Returns & leverage

See full
Return on equity-882.8%
Debt / equity0.1×
Current ratio1.9×-1.0×

Where this comes from

Calculated from BioCryst Pharmaceuticals’s reported figures.

Based on trailing twelve months.

The official record: BioCryst Pharmaceuticals’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about BioCryst Pharmaceuticals's gross margin.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is BioCryst Pharmaceuticals's gross margin?
BioCryst Pharmaceuticals (BCRX) reported gross margin of 97.8% in Q1 2026.
How has BioCryst Pharmaceuticals's gross margin changed year-over-year?
BioCryst Pharmaceuticals's gross margin increased by 0.9% year-over-year, from 96.9% to 97.8%.
What is the long-term trend for BioCryst Pharmaceuticals's gross margin?
Over 5 years (2020 to 2025), BioCryst Pharmaceuticals's gross margin has grown at a 1.4% compound annual growth rate (CAGR), from 91.3% to 97.8%.
What does gross margin mean?
Gross profit (revenue minus cost of revenue) as a percentage of revenue, on a trailing-twelve-month basis. Measures how much of each sales dollar survives the direct cost of producing the goods or services sold.